Kinase inhibitor for cognitive disorders
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
180
NCT06206824
Leucettinib-21 First-in-Human Phase 1 in Healthy Volunteers and Subjects With Down Syndrome and Alzheimer's Disease
Phase: Phase 1
Role: Lead Sponsor
Start: Jan 18, 2024
Completion: Jul 31, 2025
NCT06279208
Phosphoproteomic Profile of Children With Down Syndrome
Phase: N/A
Start: Mar 18, 2024
Completion: Apr 16, 2025
Loading map...